Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2002
Business Overview: Bio-Rad manufactures and supplies products and systems for life science research, healthcare, and analytical chemistry markets, focusing on separating, identifying, analyzing, and purifying chemical and biological materials.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2002 |
Six Months Ended June 30, 2002 |
|---|---|---|
| Net Sales | $214.7 million | $424.8 million |
| Gross Profit | $122.3 million | $243.6 million |
| Gross Margin | 57.0% | 57.3% |
| Net Income | $16.2 million | $35.0 million |
| Diluted EPS | $0.62 | $1.35 |
| Operating Cash Flow (6mo) | $38.0 million | |
| Cash & Equivalents (End of Period) | $25.7 million | |
| Total Debt (Current + Long-term) | $160.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9.9% for the quarter and 6.7% for the six-month period compared to the prior year. Adjusting for currency and divestitures, organic sales growth was 11.1% for the six months.
- Profitability: Net income rose 40.4% for the quarter and 73.9% for the six months. Gross margins improved to 57.0% (Q2) and 57.3% (6mo) from 55.4% and 54.8% respectively, driven by a favorable sales mix toward higher-margin consumables and the divestiture of the lower-margin spectroscopy business.
- Debt Reduction: The Company repaid the final $22.5 million of its Term Loan in Q2 2002, reducing total debt significantly compared to the prior year.
- Foreign Exchange: Foreign exchange losses increased to $2.1 million for the quarter (from $0.03 million) and $2.8 million for the six months (from $0.8 million), primarily due to losses in Brazilian and Russian subsidiaries.
- Accounting Changes: The Company adopted SFAS No. 142, ceasing goodwill amortization effective January 1, 2002. This eliminated approximately $8.0 million in annual amortization expense.
Guidance, Outlook, and Risks
- Outlook: Management plans to reinvest 9% to 10% of sales in research and development. The Company is constructing new facilities in Northern California with an estimated cost of $25 million, expected to take 15 months to complete.
- Acquisitions: On June 28, 2002, Bio-Rad acquired the microarray and robotics technologies business of Virtek Biotech Inc. for approximately $7 million. The Company continues to review potential acquisitions but notes that material deals may require increased borrowing.
- Risks:
- Currency Exposure: Significant exposure to foreign exchange fluctuations, particularly the Brazilian Real, which is expensive to hedge due to high local borrowing rates.
- Inventory Levels: Inventories increased by $15.6 million year-to-date, partly due to currency translation and preparation for new product launches in Fall 2002.
- Investment Impairment: A $2.0 million non-cash charge was recorded in Q1 2002 for the write-down of the investment in Digilab, LLC.
Investor Verification Checklist
- Verify the sustainability of gross margin improvements given the one-time impact of the spectroscopy divestiture and the shift to consumables.
- Monitor foreign exchange hedging strategies and exposure to the Brazilian Real and other volatile currencies.
- Assess the integration and revenue contribution of the Virtek Biotech acquisition in the Life Science segment.
- Review the progress and capitalization of the new $25 million Northern California facility construction.
- Confirm that inventory build-up aligns with actual demand for new product launches to avoid future write-downs.